Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors

Abstract

In conclusion, the current retrospective study shows that lenograstim and filgrastim are similar in terms of efficacy for the mobilization of hematopoietic stem cells in healthy donors.

The current status in hematopoietic stem cell mobilization

“…Both lenograstim, a glycosylated form and filgrastim, a nonglycosylated form of G‐CSF, have been used for stem cell mobilization. Recent data support the similar efficacy of these two agents in healthy donors . It has been reported that both of these agents can achieve effective stem cell mobilization yield after chemotherapy.…”

Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

“…The recommended dose is 10 mg/kg body weight/day, either as a single or split dose. Several studies have demonstrated the superiority of G-CSF as a single agent compared with granulocyte macrophage (GM)-CSF (sargramostim) or combination growth factor support [3][4][5][6][7][8][9][10][11][12][13][14][15]. Equivalent split dosing (5 mg/kg twice daily) or higher split dosing (12 mg/kg twice daily) has been reported to result in higher collection yields with shorter collection times; however, the toxicities of bone pain, fatigue, and headaches were more frequent, and costs were higher [7][8][9][10].…”

“…Filgrastim (nonglycosylated G-CSF), which is most commonly used in the United States, has been compared with lenograstim (glycosylated G-CSF), which is widely used in Europe, with similar reported outcomes [14,15]. Although the longer acting pegylated G-CSF (pegfilgrastim) is effective, little data support its use given the possibly increased toxicities and higher costs [16,17].…”